

# Acute megakaryoblastic leukaemia (AMKL)

Acute megakaryoblastic leukaemia (AMKL) is a rare, fast-growing blood cancer. Find out what it is, who might get it and the signs and symptoms. We also provide information on how it is diagnosed and treated.

## Summary

- Acute megakaryoblastic leukaemia (AMKL) is a rare, fast-growing blood cancer.
- We do not know the exact cause of AMKL, but it is not because of anything you have or have not done.
- AMKL is usually diagnosed from blood tests and bone marrow tests.
- Treatment for AMKL varies from person to person. It usually involves chemotherapy, sometimes followed by a stem cell transplant.
- It can be hard dealing with side effects and treatment. Ask your friends, family, medical team or Leukaemia Care if you need support.

[Download our factsheet about AMKL](#) 

---

## About AMKL

Acute megakaryoblastic leukaemia (AMKL) is a fast-growing blood cancer. It is a rare type of [acute myeloid leukaemia](#) (AML). AMKL develops when blood-forming cells called megakaryocytes divide and mature uncontrollably. They build up in your bone marrow and stop it making enough healthy blood cells.

AMKL is very rare. It can affect people of any age.

- Children with [Down's syndrome](#) have a higher chance of getting AMKL than other people. But it is still very rare.
- AMKL can also affect children without Down's syndrome, but this is less likely.
- AMKL is even rarer in adults.

People with AMKL have [genetic changes in their blood-forming cells](#). These make the cells grow out of control. The genetic changes usually happen by chance. They cannot usually be passed on to other people in your family.

<https://lcdemo-stage.gb.aldryn.io/about-leukaemia/types/acute-megakaryoblastic-leukaemia-amkl/>

Leukaemia Care Registered Charity Number 1183890. Scotland Registered Charity Number SC049802

Helpline: [08088 010 444](tel:08088010444)

We do not know the exact cause of AMKL. But it is not because of anything you have or have not done.

[Back to top](#)

---

## Signs and symptoms of AMKL

The signs and symptoms of AMKL might include:

- Infections
- Low red blood cell count (anaemia)
- Bruising or bleeding
- A swollen spleen or liver
- Swollen lymph nodes
- Extreme tiredness
- Night sweats
- Pale skin (this may look different on black or brown skin)

AMKL is usually diagnosed from blood tests and bone marrow tests.

[Back to top](#)

---

## Treating AMKL

Treatment for AMKL varies from person to person. There is no standard approach and different doctors might use different options. Your haematology team will suggest the most suitable [treatment option](#) for you. They should explain what it is, how you have it and what you can expect from it.

- Children with Down's syndrome are likely to have a combination of chemotherapy medicines. They often respond well to chemotherapy and may not need further treatment.
- Adults and children without Down's syndrome are also likely to have chemotherapy as their first treatment. After chemotherapy they may also need a [stem cell transplant](#).
- Your team might suggest treatment as part of a [clinical trial](#), if there is one suitable for you. This could let you access treatments that would not otherwise be available. It is your choice whether or not to take part.

<https://lcdemo-stage.gb.aldryn.io/about-leukaemia/types/acute-megakaryoblastic-leukaemia-amkl/>

Leukaemia Care Registered Charity Number 1183890. Scotland Registered Charity Number SC049802

Helpline: [08088 010 444](tel:08088010444)

The outcome of AMKL varies from person to person. Your medical team are best placed to discuss what they expect for you.

**It can be hard dealing with treatment and its side effects. Don't be afraid to ask for help from family, friends, your medical team or [Leukaemia Care](#).**

## Chemotherapy for AMKL

- Chemotherapy for AMKL happens in cycles or phases.
- You usually have a combination of different chemotherapy medicines. This varies from person to person. Your team will tell you what medicines they recommend for you.
- You have different medicines on different days, with some rest days between treatment. Your team can tell you what you'll have on each day.
- You usually stay in hospital to have treatment. Your team can give you an idea of how long you might need to stay in.

## Stem cell transplant

- A [stem cell transplant](#) replaces damaged or abnormal blood-forming cells in your bone marrow with healthy ones. These usually come from a donor. Sometimes this is a family member.
- If you need a stem cell transplant, your team will explain what it involves. It is an intensive form of treatment and it is not suitable for everyone.
- You usually need to stay in hospital for several weeks to have it.

[Back to top](#)

### Sources we used to develop this information

Dima D, Oprita L, Rosu AM, Trifa A, Selicean C, Moisiu V, Frinc I, Zdrenghea M, Tomuleasa C. Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR-ABL transcripts. *OncoTargets and Therapy*. 2017 Oct 19:5047-51.

Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood*. 2022 Sep 22;140(12):1345-77.

Garnett C, Cruz Hernandez D, Vyas P. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome. *IUBMB Life*. 2020 Jan;72(1):119-30.

Goemans BF, Noort S, Blink M, Wang YD, Peters ST, Van Wouwe JP, Kaspers G, de Haas V, Kollen WJ, van der Velden VH, Gruber TA. Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia. *Leukemia*. 2021 Aug;35(8):2403-6.

Gruber TA, Downing JR. The biology of pediatric acute megakaryoblastic leukemia. *Blood*. 2015 Aug 20;126(8):943-9.

Hahn AW, Li B, Prouet P, Giri S, Pathak R, Martin MG. Acute megakaryocytic leukemia: What have we learned. *Blood Reviews*. 2016 Jan 1;30(1):49-53.

Kudo K, Hama A, Kojima S, Ishii R, Morimoto A, Bessho F, Sunami S, Kobayashi N, Kinoshita A, Okimoto Y, Tawa A. Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy. *International Journal of Hematology*. 2010 May;91:630-5.

Masetti R, Guidi V, Ronchini L, Bertuccio NS, Locatelli F, Pession A. The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children. *Critical Reviews in Oncology/Hematology*. 2019 Jun 1;138:132-8.

Masoumi-Dehshiri R, Hashemi AS, Neamatzadeh H, Zare-Zardeini H. A case report: acute myeloid leukemia (FAB M7). *Iranian Journal of Pediatric Hematology and Oncology*. 2014;4(4):188.

McNulty M, Crispino JD. Acute megakaryocytic leukemia. *Cold Spring Harbor Perspectives in Medicine*. 2020 Feb 1;10(2):a034884.

Olatunji PO. A case of acute megakaryoblastic leukaemia (FAB M7), a rare type of acute myeloid leukemia (AML), in a teenager. *Malawi Medical Journal*. 2018 Dec 31;30(4):298-301.

Tanaka T, Kudo K, Kanezaki R, Yuzawa K, Toki T, Okuse R, Kobayashi A, Sato T, Kamio T, Terui K, Ito E. Antileukemic effect of azacitidine, a DNA methyltransferase inhibitor, on cell lines of myeloid leukemia associated with Down syndrome. *Experimental Hematology*. 2024 Apr 1;132:104179.

Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y, Gerbing RB. Improved outcomes for myeloid leukemia of Down syndrome: a

report from the Children's Oncology Group AAML0431 trial. Blood. 2017 Jun 22;129(25):3304-13.

Zhao G, Wu W, Wang X, Gu J. Clinical diagnosis of adult patients with acute megakaryocytic leukemia. Oncology Letters. 2018 Dec 1;16(6):6988-97.

---

## Need support?

You are not alone. We're here for you whether you have a diagnosis yourself or know someone who has. If you'd like advice, support, or a listening ear, call our freephone helpline on 08088 010 444 or send a WhatsApp message to 07500 068 065.

[Talk to us →](#)

---

## Help us improve our information

We aim to provide information that's reliable, up-to-date, and covers what matters to you. Please complete our short survey to help us improve our information and make sure it meets your needs.

[Complete our short survey →](#)

## About our information

This information is aimed at people in the UK. We do our best to make sure it is accurate and up to date but it should not replace advice from your health professional. Find out more [about our information](#).

---

Page last reviewed: 31 March 2025

Updated January 2026

Next review due: 31 March 2028